AI-Designed COVID Vaccine Passes First Human Trial

Published JUN 5

story

Above: Entrance sign to the Cambridge Biomedical Campus in Cambridge, U.K., on Oct. 20, 2025. Image credit: Jason Alden/Bloomberg/Getty Images

The Spin

An AI-designed universal vaccine just passed its first human trial safely, with zero significant side effects across all 39 volunteers — and that's a massive deal. Unlike traditional vaccines that chase mutating viruses, this Cambridge-built super-antigen targets shared features across entire virus families, meaning it could protect against pathogens that haven't even jumped to humans yet. This is vaccine development finally getting ahead of the next pandemic instead of scrambling to catch up.

University of Cambridge on X University of Cambridge

Calling a 39-person trial proof of safety is exactly the kind of rushed thinking that got the world into trouble with COVID mRNA shots, where proper toxicology was skipped, trial data was misreported and serious adverse events were buried. A retracted but extensively documented review found the risk-benefit math on novel vaccine platforms consistently favored harm over protection, especially for healthy people with near-zero infection fatality risk. Excitement over AI-designed antigens means nothing if the same regulatory shortcuts get repeated.

Andrew Bridgen on X Cureus

Metaculus Prediction

There is a 70% chance that a Type III pan-coronavirus vaccine will be approved by the U.S., U.K., EU, or Canada by 2032, according to the Metaculus prediction community.